Cargando…
High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma
SIMPLE SUMMARY: This study aimed to assess the prognostic relevance of soluble serum PD-L1 in upper tract urothelial carcinoma (UTUC) patients who underwent surgical or systemic (chemo- or immune checkpoint inhibitor) therapy. We found that high preoperative sPD-L1 levels were correlated with higher...
Autores principales: | Széles, Ádám, Kovács, Petra Terézia, Csizmarik, Anita, Váradi, Melinda, Riesz, Péter, Fazekas, Tamás, Váncsa, Szilárd, Hegyi, Péter, Oláh, Csilla, Tschirdewahn, Stephan, Darr, Christopher, Krafft, Ulrich, Grünwald, Viktor, Hadaschik, Boris, Horváth, Orsolya, Nyirády, Péter, Szarvas, Tibor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599956/ https://www.ncbi.nlm.nih.gov/pubmed/36289821 http://dx.doi.org/10.3390/biomedicines10102560 |
Ejemplares similares
-
Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial Carcinoma
por: Kovács, Petra Terézia, et al.
Publicado: (2022) -
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis
por: Széles, Ádám, et al.
Publicado: (2022) -
High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy
por: Krafft, Ulrich, et al.
Publicado: (2021) -
Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study
por: Váradi, Melinda, et al.
Publicado: (2023) -
Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
por: Olah, Csilla, et al.
Publicado: (2020)